SG11201908114UA - Pyrimidopyrimidinones useful as wee-1 kinase inhibitors - Google Patents
Pyrimidopyrimidinones useful as wee-1 kinase inhibitorsInfo
- Publication number
- SG11201908114UA SG11201908114UA SG11201908114UA SG11201908114UA SG 11201908114U A SG11201908114U A SG 11201908114UA SG 11201908114U A SG11201908114U A SG 11201908114UA SG 11201908114U A SG11201908114U A SG 11201908114UA
- Authority
- SG
- Singapore
- Prior art keywords
- almac
- craigavon
- house
- international
- seagoe
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1703881.1A GB201703881D0 (en) | 2017-03-10 | 2017-03-10 | Pharmaceutical compounds |
| PCT/GB2018/050620 WO2018162932A1 (en) | 2017-03-10 | 2018-03-12 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908114UA true SG11201908114UA (en) | 2019-10-30 |
Family
ID=58605309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908114U SG11201908114UA (en) | 2017-03-10 | 2018-03-12 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11208413B2 (hr) |
| EP (1) | EP3592745B1 (hr) |
| JP (1) | JP7244430B2 (hr) |
| KR (1) | KR102605546B1 (hr) |
| CN (1) | CN110603256B (hr) |
| AU (1) | AU2018231671B2 (hr) |
| BR (1) | BR112019018753A2 (hr) |
| CA (1) | CA3055874A1 (hr) |
| CL (1) | CL2019002557A1 (hr) |
| CY (1) | CY1124613T1 (hr) |
| DK (1) | DK3592745T3 (hr) |
| EA (1) | EA201992137A1 (hr) |
| ES (1) | ES2895365T3 (hr) |
| GB (1) | GB201703881D0 (hr) |
| HR (1) | HRP20211652T1 (hr) |
| HU (1) | HUE056220T2 (hr) |
| IL (1) | IL269063B (hr) |
| LT (1) | LT3592745T (hr) |
| MA (1) | MA47736B1 (hr) |
| MX (1) | MX2019010554A (hr) |
| MY (1) | MY195580A (hr) |
| PH (1) | PH12019502049A1 (hr) |
| PL (1) | PL3592745T3 (hr) |
| PT (1) | PT3592745T (hr) |
| RS (1) | RS62464B1 (hr) |
| SA (1) | SA519410093B1 (hr) |
| SG (1) | SG11201908114UA (hr) |
| SI (1) | SI3592745T1 (hr) |
| UA (1) | UA125093C2 (hr) |
| WO (1) | WO2018162932A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018347307A1 (en) | 2017-10-09 | 2020-04-23 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| WO2019074979A1 (en) | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| EP3952877A4 (en) | 2019-04-09 | 2022-12-14 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| US20220162229A1 (en) * | 2019-04-09 | 2022-05-26 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| EP3952878A4 (en) * | 2019-04-09 | 2023-01-04 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| CA3237756A1 (en) * | 2021-11-09 | 2023-05-19 | Hangzhou Glubio Pharmaceutical Co., Ltd. | Wee1 protein kinase degradation agent and use thereof |
| WO2023170065A1 (en) * | 2022-03-07 | 2023-09-14 | Debiopharm International S.A. | Methods of treating small cell lung cancer |
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8577501A1 (es) | 2002-07-25 | 2004-02-07 | Warner Lambert Co | Inhibidores de quinasas |
| AR060635A1 (es) * | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
| AU2009325400A1 (en) * | 2008-12-12 | 2010-06-17 | Msd K.K. | Dihydropyrimidopyrimidine derivatives |
| JP2015511245A (ja) * | 2012-02-23 | 2015-04-16 | アッヴィ・インコーポレイテッド | ピリドピリミジノン系キナーゼ阻害薬 |
| GB201306610D0 (en) * | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201322602D0 (en) * | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
-
2017
- 2017-03-10 GB GBGB1703881.1A patent/GB201703881D0/en not_active Ceased
-
2018
- 2018-03-12 CN CN201880016390.8A patent/CN110603256B/zh active Active
- 2018-03-12 DK DK18711666.0T patent/DK3592745T3/da active
- 2018-03-12 MX MX2019010554A patent/MX2019010554A/es unknown
- 2018-03-12 LT LTEPPCT/GB2018/050620T patent/LT3592745T/lt unknown
- 2018-03-12 EA EA201992137A patent/EA201992137A1/ru unknown
- 2018-03-12 HU HUE18711666A patent/HUE056220T2/hu unknown
- 2018-03-12 JP JP2019548963A patent/JP7244430B2/ja active Active
- 2018-03-12 BR BR112019018753A patent/BR112019018753A2/pt unknown
- 2018-03-12 AU AU2018231671A patent/AU2018231671B2/en active Active
- 2018-03-12 EP EP18711666.0A patent/EP3592745B1/en active Active
- 2018-03-12 WO PCT/GB2018/050620 patent/WO2018162932A1/en active Application Filing
- 2018-03-12 HR HRP20211652TT patent/HRP20211652T1/hr unknown
- 2018-03-12 RS RS20211277A patent/RS62464B1/sr unknown
- 2018-03-12 CA CA3055874A patent/CA3055874A1/en active Pending
- 2018-03-12 PT PT187116660T patent/PT3592745T/pt unknown
- 2018-03-12 MA MA47736A patent/MA47736B1/fr unknown
- 2018-03-12 SG SG11201908114U patent/SG11201908114UA/en unknown
- 2018-03-12 UA UAA201910268A patent/UA125093C2/uk unknown
- 2018-03-12 MY MYPI2019005160A patent/MY195580A/en unknown
- 2018-03-12 SI SI201830430T patent/SI3592745T1/sl unknown
- 2018-03-12 US US16/492,292 patent/US11208413B2/en active Active
- 2018-03-12 PL PL18711666T patent/PL3592745T3/pl unknown
- 2018-03-12 KR KR1020197029457A patent/KR102605546B1/ko active IP Right Grant
- 2018-03-12 ES ES18711666T patent/ES2895365T3/es active Active
-
2019
- 2019-09-02 IL IL269063A patent/IL269063B/en unknown
- 2019-09-06 CL CL2019002557A patent/CL2019002557A1/es unknown
- 2019-09-09 PH PH12019502049A patent/PH12019502049A1/en unknown
- 2019-09-10 SA SA519410093A patent/SA519410093B1/ar unknown
-
2021
- 2021-10-20 CY CY20211100913T patent/CY1124613T1/el unknown
- 2021-12-03 US US17/541,362 patent/US20220194947A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201903456WA (en) | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201900545TA (en) | Pharmaceutical compounds | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201908743SA (en) | Methods and compositions for modulation of immune cells | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same |